Literature DB >> 18997294

Apolipoprotein E highly correlates with AbetaPP- and tau-related markers in human cerebrospinal fluid.

Simona Vuletic1, Ge Li, Elaine R Peskind, Hal Kennedy, Santica M Marcovina, James B Leverenz, Eric C Petrie, Virginia M-Y Lee, Douglas Galasko, Gerard D Schellenberg, John J Albers.   

Abstract

We assessed cerebrospinal fluid (CSF) levels of apolipoprotein E (apoE), phospholipid transfer protein (PLTP) activity, cholesterol, secreted amyloid-beta protein precursor alpha and beta (sAbetaPPalpha, sAbetaPPbeta), amyloid-beta peptides 1-40 (Abeta_{40}) and 1-42 (Abeta_{42}), total tau and tau phosphorylated at threonine 181 (pTau) in neurologically healthy, cognitively intact adults. ApoE significantly correlated with sAbetaPPalpha (r = 0.679), sAbetaPPbeta (r = 0.634), Abeta_{40} (r = 0.609), total and pTau (r = 0.589 and r = 0.673, respectively, all p < 0.001), PLTP activity (r = 0.242, p = 0.002) and cholesterol (r = 0.194, p < 0.01). PLTP activity significantly correlated with sAbetaPPalpha (r = 0.292), sAbetaPPbeta (r = 0.281), total and pTau (r = 0.265 and 0.258, respectively; all p <or= 0.001). Using partial correlations of CSF biomarkers with apoE, PLTP activity, age and gender, apoE remained significantly correlated with sAbetaPPalpha, sAbetaPPbeta, Abeta_{40}, total and pTau (p < 0.001). The presence of apoE epsilon2 was associated with lower levels of apoE, PLTP activity and Abeta_{42}, while APOEepsilon4} had no significant impact on any of the measured variables. Our data suggest that there is a significant physiological link between apoE and AbetaPP, as well as between apoE and tau in neurologically healthy, cognitively intact individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997294      PMCID: PMC2667787          DOI: 10.3233/jad-2008-15307

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  50 in total

1.  Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE varepsilon4.

Authors:  Rudi K Tannenberg; Heather L Scott; Anthony E G Tannenberg; Peter R Dodd
Journal:  Neurochem Int       Date:  2006-06-30       Impact factor: 3.921

2.  Apolipoprotein E-epsilon 2 and Alzheimer's disease: genotype influences pathologic phenotype.

Authors:  C F Lippa; T W Smith; A M Saunders; C Hulette; D Pulaski-Salo; A D Roses
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

3.  Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease.

Authors:  K Johnson-Wood; M Lee; R Motter; K Hu; G Gordon; R Barbour; K Khan; M Gordon; H Tan; D Games; I Lieberburg; D Schenk; P Seubert; L McConlogue
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

Review 4.  Discoveries of tau, abnormally hyperphosphorylated tau and others of neurofibrillary degeneration: a personal historical perspective.

Authors:  Khalid Iqbal; Inge Grundke-Iqbal
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

Review 5.  Apolipoprotein E: a cholesterol transport protein with lipid transport-independent cell signaling properties.

Authors:  D K Swertfeger; D Y Hui
Journal:  Front Biosci       Date:  2001-03-01

6.  Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE.

Authors:  E Masliah; W Samuel; I Veinbergs; M Mallory; M Mante; T Saitoh
Journal:  Brain Res       Date:  1997-03-21       Impact factor: 3.252

7.  The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E.

Authors:  E E Windler; P T Kovanen; Y S Chao; M S Brown; R J Havel; J L Goldstein
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

8.  Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.

Authors:  T Wisniewski; E M Castaño; A Golabek; T Vogel; B Frangione
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

9.  The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Authors:  Lidia Glodzik-Sobanska; Elizabeth Pirraglia; Miroslaw Brys; Susan de Santi; Lisa Mosconi; Kenneth E Rich; Remigiusz Switalski; Leslie Saint Louis; Martin J Sadowski; Frank Martiniuk; Pankaj Mehta; Domenico Pratico; Raymond P Zinkowski; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-10-24       Impact factor: 4.673

10.  Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease.

Authors:  C Berr; J J Hauw; P Delaère; C Duyckaerts; P Amouyel
Journal:  Neurosci Lett       Date:  1994-09-12       Impact factor: 3.046

View more
  5 in total

1.  CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease.

Authors:  Jeremy Koppel; Fabien Campagne; Valérie Vingtdeux; Ute Dreses-Werringloer; Michael Ewers; Dan Rujescu; Harald Hampel; Marc L Gordon; Erica Christen; Julien Chapuis; Blaine S Greenwald; Peter Davies; Philippe Marambaud
Journal:  Mol Med       Date:  2011-05-24       Impact factor: 6.354

Review 2.  Role of plasma phospholipid transfer protein in lipid and lipoprotein metabolism.

Authors:  John J Albers; Simona Vuletic; Marian C Cheung
Journal:  Biochim Biophys Acta       Date:  2011-06-28

3.  Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables.

Authors:  Simona Vuletic; Hal Kennedy; John J Albers; Joep Killestein; Hugo Vrenken; Dieter Lütjohann; Charlotte E Teunissen
Journal:  Mult Scler Relat Disord       Date:  2014-07-01       Impact factor: 4.339

4.  The "Alzheimer's disease signature": potential perspectives for novel biomarkers.

Authors:  Sergio Davinelli; Mariano Intrieri; Claudio Russo; Alfonso Di Costanzo; Davide Zella; Paolo Bosco; Giovanni Scapagnini
Journal:  Immun Ageing       Date:  2011-09-20       Impact factor: 6.400

5.  Genomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease.

Authors:  Puneet Talwar; Yumnam Silla; Sandeep Grover; Meenal Gupta; Rachna Agarwal; Suman Kushwaha; Ritushree Kukreti
Journal:  BMC Genomics       Date:  2014-03-15       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.